Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImOPac

Financiado

Cerrado

GemciTest An innovative In Vitro Diagnostic for the decision making process of...

GemciTest An innovative In Vitro Diagnostic for the decision making process of pancreatic cancer treatment Acobiom is a French Biotech SME (SAS, 8 employees). Since its foundation, June 1999, Acobiom has always been at the forefront of medical innovation, in particular in biomarker discovery and diagnostic development, thanks to its ex... ver más

31/01/2021

ACOBIOM

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ACOBIOM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ACOBIOM

50.00K€ | Lider

COMERCIAL DE LA FORJA

575.11K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRECEDE PRECEDE PancREatic Cancer Early DEtection 71K€ Cerrado

PANCAID PANcreatic CAncer Initial Detection via liquid biopsy 10M€ Cerrado

SenolT Fast and effective diagnostic test for the early detection o... 71K€ Cerrado

CANDLE Cancer Diagnosis by Multiplex Protein Epitope Profiling 71K€ Cerrado

PTA2020-018315-I Implementación de la Plataforma de Biomarcadores de Oncologí... 42K€ Cerrado

PROSENSE Cancer Diagnosis Parallel Sensing of Prostate Cancer Biomar... 4M€ Cerrado

Duración del proyecto: 14 meses Fecha Inicio: 2019-11-20
Fecha Fin: 2021-01-31

Líder del proyecto

ACOBIOM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Acobiom is a French Biotech SME (SAS, 8 employees). Since its foundation, June 1999, Acobiom has always been at the forefront of medical innovation, in particular in biomarker discovery and diagnostic development, thanks to its expertise and knowledge in genomics, transcriptomics, bioinformatics, and data science. In 2011, Acobiom began working to address the problem of pancreatic cancer. Pancreatic cancer is currently the 4th leading cause of cancer death in Western Countries. If no action is taken, it will rise to be second in 2020. For nearly 80% of patients (~51K and ~150K in USA and EU patients in 2017), diagnosis occurs at an advanced, non-surgical stage, making them incurable. The high mortality rate, with more than 95% of patients dead at 5 years, versus 13% for breast cancer, is partly due to the difficulty to diagnose, but also because of the lack of stratification of patients and a limited choice for treatments in the current decision-making process. There are currently three major chemotherapy regimens for the pancreatic cancer, and up until now, the decisional algorithm in metastatic pancreatic ductal adenocarcinoma (PDAC) management does not mention pharmacogenomics biomarkers, needed to stratify patient populations and to choose the best treatment with the best clinical effectiveness for a given patient. These regimens have very different toxicities profiles which factors in to which regimen is recommended. Through ImOPac project, Acobiom aims to implement an innovative approach to improve personalized pancreatic cancer management in the decision-making process of PDAC, by using biomarkers to help in the patient stratification. This approach is the GemciTest, a non-invasive test based on an 11-gene blood signature score. Thanks to this innovation, Acobiom has an opportunity to create an EU new market estimated at 360 M€, and leading to a 34 M€ turnover by 2024.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores